References
- Bibbiani F, Costantini LC, Patel R,. et al. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005;192:73-8
- Olanow CW, Obeso JA, Stocchi F, Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
- Smith LA, Jackson MJ, Al-Barghouthy G,. et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005; 20:306-14
- Nutt JG, Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007; 22:1-9
- Adler CH, Sethi KD, Hauser RA,. et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-9
- Brunt ER, Brooks DJ, Korczyn AD,. et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502
- Korczyn AD, Brunt ER, Larsen JP,. et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999;53:364-70
- Lieberman A, Olanow CW, Sethi K,. et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-62
- Rascol O, Brooks DJ, Korczyn AD,. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91
- Hauser RA, Rascol O, Korczyn AD,. et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-17
- Tompson DJ, Vearer D, Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007;29:2654-66
- Ezzet F, Whitehead J, A random effects model for binary data from cross-over trials. Applied Statistics 1992; 42: 117-126
- Piaggio G, Elbourne DR, Altman DG,. et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-60
- Tompson DJ, Oliver-Willwong R, Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patient's with Parkinson's disease. Clin Neuropharmacol 2008. In press.
- Requip/Requip Modutab [Swiss summary of product characteristics]. http://www.kompendium.ch/Monographie. aspx?Id=d40f2ff7-8630-4de1-832f-88be6f9463f1&lang=de& MonType=fi
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-8
- Giladi N, Boroojerdi B, Korczyn AD,. et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404
- Barone P, Bravi D, Bermejo-Pareja F,. et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53:573-9